Lunch Briefing Hosted by Cytiva
Time: 1:00 pm
day: Day One
Leveraging Lessons from the COVID-19 Pandemic to Accelerate the Development and Production of Adeno-Associated Virus (AAV)-Based Gene Therapies
While there are currently over 1400 clinical cell and gene therapy programs, trial recruitment, raw material supply chains, and low-yield processes are just some of the multiple challenges facing the industry. The recent pandemic revealed that with the proper framework, a drug product can be developed, clinically tested, and produced for hundreds of millions of patients in less than a year.
- What lessons can we apply from this effort for AAV development and production?
- How can we rethink regulatory filing strategy?
- And why does the cell and gene therapy arena so urgently need these learnings?